These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 29377455)

  • 21. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1).
    He SM; Li R; Kanwar JR; Zhou SF
    Curr Med Chem; 2011; 18(3):439-81. PubMed ID: 21143116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simotinib as a modulator of P-glycoprotein: substrate, inhibitor, or inducer?
    Huang L; Shen C; Chen Y; Yan H; Cheng Z; Zhu Q
    Anticancer Drugs; 2016 Apr; 27(4):300-11. PubMed ID: 26766493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological strategies for overcoming multidrug resistance.
    Nobili S; Landini I; Giglioni B; Mini E
    Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S; Robey RW; Bates SE; Ambudkar SV
    Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The structure and functions of P-glycoprotein.
    Li Y; Yuan H; Yang K; Xu W; Tang W; Li X
    Curr Med Chem; 2010; 17(8):786-800. PubMed ID: 20088754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective inhibition of P-gp transporter by goniothalamin derivatives sensitizes resistant cancer cells to chemotherapy.
    Sachs J; Kadioglu O; Weber A; Mundorf V; Betz J; Efferth T; Pietruszka J; Teusch N
    J Nat Med; 2019 Jan; 73(1):226-235. PubMed ID: 30066239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular trafficking of P-glycoprotein.
    Fu D; Arias IM
    Int J Biochem Cell Biol; 2012 Mar; 44(3):461-4. PubMed ID: 22212176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells.
    Nanayakkara AK; Follit CA; Chen G; Williams NS; Vogel PD; Wise JG
    Sci Rep; 2018 Jan; 8(1):967. PubMed ID: 29343829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
    Zhou SF
    Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of p-glycoprotein--lead identification and optimisation.
    Pleban K; Ecker GF
    Mini Rev Med Chem; 2005 Feb; 5(2):153-63. PubMed ID: 15720285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
    Callaghan R; Higgins CF
    Br J Cancer; 1995 Feb; 71(2):294-9. PubMed ID: 7841043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Localization of the 1,4-dihydropyridine drug acceptor of P-glycoprotein to a cytoplasmic domain using a permanently charged derivative N-methyl dexniguldipine.
    Ferry D; Boer R; Callaghan R; Ulrich WR
    Int J Clin Pharmacol Ther; 2000 Mar; 38(3):130-40. PubMed ID: 10739116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier.
    Demeule M; Régina A; Jodoin J; Laplante A; Dagenais C; Berthelet F; Moghrabi A; Béliveau R
    Vascul Pharmacol; 2002 Jun; 38(6):339-48. PubMed ID: 12529928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability.
    Drori S; Eytan GD; Assaraf YG
    Eur J Biochem; 1995 Mar; 228(3):1020-9. PubMed ID: 7737146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the dexniguldipine binding site in the multidrug resistance-related transport protein P-glycoprotein by photoaffinity labeling and mass spectrometry.
    Borchers C; Boer R; Klemm K; Figala V; Denzinger T; Ulrich WR; Haas S; Ise W; Gekeler V; Przybylski M
    Mol Pharmacol; 2002 Jun; 61(6):1366-76. PubMed ID: 12021398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
    Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
    Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model.
    Zhang Q; Zhai S; Li L; Li X; Jiang C; Zhang C; Yan B
    J Pharmacol Sci; 2014; 126(1):66-76. PubMed ID: 25185500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial localization of P-glycoprotein in the human breast cancer cell line MCF-7/ADM and its functional characterization.
    Shen Y; Chu Y; Yang Y; Wang Z
    Oncol Rep; 2012 May; 27(5):1535-40. PubMed ID: 22307172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multidrug Resistance in HCC827 Cells.
    Tomono T; Yano K; Ogihara T
    J Pharm Sci; 2017 Sep; 106(9):2642-2649. PubMed ID: 28322937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.